Home
overview
With staggering growth rates, the booming Biopharmaceutical industry has been increasingly diverting resources to protein research.

Great contributions have been made through academic research but it is the pharmaceutical industry that solely faces unique challenges, in its strive to progress compounds into novel drugs:

  • Targeting Expression and purification demands
  • Optimizing Efficacy and activity levels
  • Meeting demands for production scale up
  • Overcoming challenges in structural research for drug design

The SMi Group’s 3rd Annual Global Protein Summit is designed to meet the needs of the industry.

Bringing together Vice Presidents, Directors, Heads and leading Researchers from the pharmaceutical industry to share successes and discuss the critical issues surrounding the development of innovative protein drug compounds. Hear contributions from leading industry experts, including:

  • Dr Niels C Kaarsholm, Corporate Vice President, Protein Engineering, Diabetes Research, Novo Nordisk
  • Dr Thomas Bumol, Vice President, Biotechnology Discovery Research and Applied Molecular Evolution,  Eli Lilly
  • Dr Robert Wynands, Director, Structural Biology, Takeda
  • Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression and Purification, Wyeth
  • Dr Niek Dekker, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca
  • Dr Cory R Brouwer, Associate Director, Knowledge Management Informatics, Pfizer
  • Dr Bernardo Perez-Ramirez, Scientific Director, Bio-Formulations Development, Genzyme
  • Dr Hans De Haard, Senior Director, Technology and Discovery, Ablynx
  • Dr Charles H Squires, Senior Director, Biopharmaceutical Services, Dowpharma
  • Dr Joey M Studts, Principal Scientist and Head, Protein Resources, Boehringer-Ingelheim
  • Dr Stephen Irving, Senior Principal Scientist, Pfizer
  • Dr Lukas Leder, Research Investigator, Protein Expression and Purification, Centre of Proteomic Chemistry, Novartis                            
  • Dr Ramkrishna Sadhukhan, Bioresearch Centre, Abbott Laboratories

The SMi Group’s 3rd Annual Global Protein Summit offers a unique opportunity to hear about the latest developments from industry leaders. Bringing together knowledge and expertise, it’s designed to create the perfect setting for the exchange of ideas and networking opportunities.

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Dr Ramkrishna  Sadhukhan

Dr Ramkrishna Sadhukhan, Senior Research Scientist, Bioresearch Centre, Abbott Laboratories

9:10 NOVEL APPROACHES FOR EFFICIENT PROTEIN PRODUCTION IN DRUG DISCOVERY

Dr Lukas Leder

Dr Lukas Leder, Research Investigator, Protein Expression and Purification, Centre of Proteomic Chemistry, Novartis

  • Versatile set of  vectors for multi-parallel expression in different host cells experimenting with novel technologies through outsourcing of lead discovery and early research
  • Streamlined procedure for a quick determination of expression levels in small culture volumes
  • Automated multi-step chromatography allowing a fast recovery of purified protein in high yields
  • 9:50 PURIFIED MEMBRANE PROTEIN IN DRUG DISCOVERY

    Dr Niek Dekker

    Dr Niek Dekker, Associate Director, Protein Engineering, Global Structural Chemistry, AstraZeneca

  • Production of mg quantities of membrane protein targets for drug discovery
  • Exploitation of these reagents for crystallography and biophysical mode of action analysis
  • Opportunities for biologics
  • 10:30 Morning Coffee

    10:50 ASSESSING THE COSTS AND REWARDS OF DIFFERENT EXPRESSION SYSTEMS FOR PROTEIN STRUCTURAL WORK

    Dr Robert  Wynands

    Dr Robert Wynands, Director, Structural Biology, Takeda

  • Analyzing the transition to higher-level expression systems based on accumulated data 
  • Valuing the possibilities of further expanding to mammalian cell expression systems
  • 11:30 INCREASING PROTEIN STABILITY DURING RECOMBINANT PROTEIN PRODUCTION

    Dr Sheena Whyte

    Dr Sheena Whyte, Project Leader, Novexin

  • Stabilisation of proteins at 4°C or over several freeze/thaw cycles
  • Maintaining the stability of fusion proteins after tag is removed
  • Increasing the concentration of difficult to handle proteins
  • Improving purification procedures by increasing the yield and quality of protein obtained
  • 12:10 Networking Lunch

    13:20 STREAMLINING EXPRESSION SCREENING IN BACULOVIRUS EXPRESSION SYSTEMS

    Dr Alycia  Shoultz

    Dr Alycia Shoultz, Scientist, Biologics and Biomolecular Sciences, Boehringer Ingelheim

  • Eliminating bottlenecks in production of eukaryotic proteins
  • Multi-paralleled expression screening in baculovirus expression systems
  • Automation of baculovirus expression screening
  • Small scale Expression analysis vs. scale-up results
  • 14:00 COMPUTER AIDED MULTI-PARAMETER GENE DESIGN

    Prof Ralf Wagner

    Prof Ralf Wagner, Chief Scientific Officer, Geneart

    Dr Stefan Weinges

    Dr Stefan Weinges, Manager, Scientific Sales Western Europe, Geneart Gmbh

    14:40 MEETING PROTEIN PRODUCTION DEMANDS THROUGHOUT THE BIOPHARMACEUTICAL DEVELOPMENT PROCESS

    Dr Zhijian Lu

    Dr Zhijian Lu, Assistant Director, Biotherapeutics Expression and Purification, Wyeth

  • Exploring the technical requirements for production aiding the stages of pre-clinical compound development
  • Structuring the technological platforms to support proteins needed for every stage
  • 15:20 Afternoon Tea

    15:40 CHARACTERIZATION AND QUANTITATION OF THERAPEUTIC MONOCLONAL ANTIBODIES USING LABCHIP SDS ELECTROPHORESIS

    Dr Bahram Fathollahi

    Dr Bahram Fathollahi, Associate Director, Microfluidics Group, Caliper Life Sciences

    • High throughput, reliable, and reproducible method
    • Labchip SDS Electrophoresis vs. CE-SDS results from Amgen study
    • Rapid determination of molecular mass, quantity, and % purity
    • Resolving between heavy chain and nonglycosylated heavy chain species present at low level

    16:20 NI-NTA / TAGZYME TECHNOLOGIES: A CASE STUDY ON LARGE-SCALE PROTEIN MANUFACTURING AND CRYSTALLIZATION

    Dr Frank Schaefer

    Dr Frank Schaefer, Associate Director, Research and Development, QIAGEN

  • Presenting a fast and convenient approach to screen a large number of expression constructs
  • Designing a manufacturing process that combines robust and well-documented technological platforms
  • The TAGZyme™ system allows the efficient and precise exoproteolytic removal of N-terminal tags from recombinant proteins
  • Provides high-purity proteins free of vector-encoded amino acids for use in applications that demand recombinant reagents, an absence of non-specific cleavage, and a complete removal of all impurities from the target-protein preparation
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Dr Hans de Haard

    Dr Hans de Haard, Senior Director, Technology and Discovery, Ablynx

    9:10 OPTIMIZING PROTEIN THERAPEUTICS AS SUCCESSFUL CLINICAL CANDIDATES

    Dr Thomas F Bumol

    Dr Thomas F Bumol, Vice President, Biotechnology Discovery Research and Applied Molecular Evolution, Eli Lilly

  • Discovery strategies for therapeutic proteins and antibodies for various therapeutic arenas
  • Review of design principles for simultaneously optimizing pharmacological efficacy and biochemical properties through protein engineering, along with preclinical and clinical examples
  • The role of deimmunization engineering
  • 9:50 PRE-FORMULATION RESEARCH AND DEVELOPMENT OF THERAPEUTIC PROTEINS

    Dr Bernardo Perez-Ramirez

    Dr Bernardo Perez-Ramirez, Scientific Director, Bio-Formulations Development, Genzyme

  • Strategies to characterize the solution behavior of proteins with limited amounts of material
  • Biophysical and thermodynamic approaches in formulation development
  • Optimizing discovery research, pre-formulation and formulation development interfaces
  • 10:30 Morning Coffee

    11:00 HIGH THROUGHPUT TECHNOLOGY OF EXPRESSED PROTEIN FOR STRUCTURAL ANALYSIS

    Richard Bazin

    Richard Bazin, Scientist, Pfizer

    11:40 HIGH LEVEL PROTEIN PRODUCTION IN MAMMALIAN CELLS BY TRANSIENT TRANSFECTION

  • Transient transfection of CHO and 293 cells in suspension cultures
  • Functional proteins (up to milligram quantities) with all post-translational modifications produced in one week
  • Simplified downstream purification of secreted proteins with FreeStyle™ serum-free medium
  • Dr Federico Katzen

    Dr Federico Katzen, Research and Development, Invitrogen

    Dr Brian   Dalby

    Dr Brian Dalby, Research and Development, Invitrogen

    12:20 GENOME-WIDE PROTEIN EXPRESSION SCREENING USING OMICSLINK™ HUMAN ORF EXPRESSION CLONES AND WHEAT GERM EXTRACT RTS™ CELL FREE

    Dr Sun Lu

    Dr Sun Lu, Executive Vice President, GeneCopoeia Inc

  • Results of a large scale collaborative project for expression screening of more than 12,000 human full length protein coding ORF clones that has been completed jointly by GeneCopoeia and Roche
  • The advantages of specially constructed OmicsLink™ human ORF expression clones and wheat germ extract RTS™ cell free system
  • Features of the protein expression database system
  • Applications of the cell free expression system, expression ready ORF clones, and recombinant proteins produced
  • 13:00 Networking Lunch

    13:50 NEW PERSPECTIVES FOR THE DIRECTED EVOLUTION OF THERAPEUTICAL PROTEINS

    Emmanuel Maille

    Emmanuel Maille, General Manager, Business Development , Proteus S A

  • Rapid cell-free and cell-based expression
  • Evosight & L-Shuffling, leading-edge technologies for protein evolution
  • New in-vitro assays for immunogenicity assessment
  • 14:30 CHALLENGES IN SCALE-UP OF A HETERODIMERIC CYTOKINE IL-23

    Dr Ramkrishna  Sadhukhan

    Dr Ramkrishna Sadhukhan, Senior Research Scientist, Bioresearch Centre, Abbott Laboratories

    • Cloning strategy
    • Expression screening and scale-up
    • Purification and characterization

    15:10 Afternoon Tea

    15:40 APPLICATION OF MICROFLUIDIC SAMPLE ANALYSIS IN HIGH-THROUGHPUT PROTEIN EXPRESSION

    Dr William Clay Brown

    Dr William Clay Brown, Scientific Director, High-Throughput Protein Lab, Life Sciences Institute, University Of Michigan

  • High-Throughput protein production allowed us to define the domains necessary for protein-protein interactions
  • Caliper Labchip allowed for rapid analysis of both DNA and protein samples
  • Widely divergent sizes could all be run together in a single analysis
  • High accuracy and reproducibility allowed for confidence in sample identification
  • Protein concentrations were within two-fold of manual Bradford values
  • 16:20 SMALLER SIZED ANTIBODIES AS NEW THERAPEUTIC ENTITIES

    Dr Hans de Haard

    Dr Hans de Haard, Senior Director, Technology and Discovery, Ablynx

    Antibody-derived therapeutic proteins based on naturally occurring heavy-chain antibodies derived from camelids
    Combining the pharmaceutical advantage of an antibody with advantageous traits of small molecule compound
    Added value brought to validated targets: the TNF-a case study

    17:00 PSEUDOMONAS FLUORESCENS-BASED EXPRESSION TECHNOLOGY FOR THE

    Dr Charles H Squires

    Dr Charles H Squires, Senior Director, Biopharmaceutical Services, Dowpharma

  • The Pseudomonas-based Pfenex system is proven for high titer protein pharmaceutical production
  • Off the shelf expression plasmids and proven host strains
  • Effective high throughput methods to identify hosts producing high levels of active target protein
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    +

    Workshops

    Decreasing Time to Protein for Assay Development to Structural Research
    Workshop

    Decreasing Time to Protein for Assay Development to Structural Research

    Danubius Hotel Regents Park
    5th June 2007
    London, United Kingdom

    Lord's Cricket Ground

    Marylebone Cricket Club
    Lord's Ground
    London NW8 8QN
    United Kingdom

    Lord's Cricket Ground

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.